Comparison of the Treatment Efficiency of Bone Marrow‐Derived Mesenchymal Stem Cell Transplantation via Tail and Portal Veins in CCl₄‐Induced Mouse Liver Fibrosis

Abstract

Because of self-renewal, strong proliferation in vitro, abundant sources for isolation, and a high differentiation capacity, mesenchymal stem cells are suggested to be potentially therapeutic for liver fibrosis/cirrhosis. In this study, we evaluated the treatment effects of mouse bone marrow-derived mesenchymal stem cells (BM-MSCs) on mouse liver cirrhosis induced by carbon tetrachloride. Portal and tail vein transplantations were examined to evaluate the effects of different injection routes on the liver cirrhosis model at 21 days after transplantation. BM-MSCs transplantation reduced aspartate aminotransferase/alanine aminotransferase levels at 21 days after injection. Furthermore, BM-MSCs induced positive changes in serum bilirubin and albumin and downregulated expression of integrins (600- to 7000-fold), transforming growth factor, and procollagen-α1 compared with the control group. Interestingly, both injection routes ameliorated inflammation and liver cirrhosis scores. All mice in treatment groups had reduced inflammation scores and no cirrhosis. In conclusion, transplantation of BM-MSCs via tail or portal veins ameliorates liver cirrhosis in mice. Notably, there were no differences in treatment effects between tail and portal vein administrations. In consideration of safety, we suggest transfusion of bone marrow-derived mesenchymal stem cells via a peripheral vein as a potential method for liver fibrosis treatment.

A Novel Hepatic Anti-Fibrotic Strategy Utilizing the Secretome Released from Etanercept-Synthesizing Adipose-Derived Stem Cells

“…Although statistically insignificant, secretome treatment also reduced the cell viability of HSCs, suggestive of anti-fibrogenic effects of secretome itself. Indeed, several studies have reported the antifibrogenic effects of mesenchymal stem cells or their secretome in the model of liver fibrosis [37][38][39][40][41][42]. Since liver fibrosis process is initiated by inflammation, it appears that secretome reduces the viability of HSCs through anti-inflammatory activities.…”

An evolution of stem cell research and therapy in Viet Nam

“…After that, the laboratory made various achievements in the development of new technologies for isolation, characterization, differentiation, and cryopreservation of various stem cells from different tissues, including adipose tissue, umbilical cord blood, and bone marrow [31][32][33][34][35]. This laboratory succeeded to differentiate MSCs into adipocytes, osteoblasts, chondrocytes, cardiomyocytes, insulin-producing cells, and neuron-like cells [36][37][38][39]. Moreover, various animal models of different diseases were also developed in order to execute pre-clinical trials [32,37,40].…”

“…This laboratory succeeded to differentiate MSCs into adipocytes, osteoblasts, chondrocytes, cardiomyocytes, insulin-producing cells, and neuron-like cells [36][37][38][39]. Moreover, various animal models of different diseases were also developed in order to execute pre-clinical trials [32,37,40]. The animal disease models treated by stem cell transplantation have included femoral head necrosis, type 1 and 2 diabetes mellitus [32], bone marrow failure, injured knee cartilage [41], aged skin, liver cirrhosis [37], hindlimb ischemia [42,43], heart failure [44], and spinal cord injury [45].…”

“…Moreover, various animal models of different diseases were also developed in order to execute pre-clinical trials [32,37,40]. The animal disease models treated by stem cell transplantation have included femoral head necrosis, type 1 and 2 diabetes mellitus [32], bone marrow failure, injured knee cartilage [41], aged skin, liver cirrhosis [37], hindlimb ischemia [42,43], heart failure [44], and spinal cord injury [45]. Besides the use of normal stem cells, the SCL has also focused on the use of cancer stem cells [46], has developed assays to evaluate drug resistance, and has investigated cancer stem cell-based targeted therapy, gene therapy [47,48], and immune cell therapy [49].…”

Transplantation of umbilical cord blood-derived mesenchymal stem cells to treat liver cirrhosis in mice: a comparison of tail and portal vein injection

“…Fixed samples were embedded in paraffin, sectioned into 5µm-thick slices and stained with Hematoxylin/Eosin (Sigma-Aldrich) and Trichrome (Sigma-Aldrich), according to previous protocols (Truong et al, 2016). Immunohistochemistry of the sections was also done according to previous protocols (Truong et al, 2016).…”